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Valdecoxib, C16H14N2O3S, is a non-steroidal anti-in¯amma-
tory drug containing a planar isoxazole heterocycle which is
substituted at the C atoms with two aromatic rings and a
methyl group. In addition to one molecule of valdecoxib, there
is half a molecule of ethyl methyl ketone in the asymmetric
unit of the title compound [systematic name: 4-(5-methyl-3-
phenylisoxazol-4-yl)benzenesulfonamide ethyl methyl ketone
hemisolvate], viz. C16H14N2O3S0.5C4H8O. The crystal
packing is stabilized by NÐH  O hydrogen bonds. Apart
from the orientation of the sulfonamide group, the conforma-
tion of the title compound agrees well with that of the recently
published orthorhombic polymorph which does not contain
any solvent.
Comment
The title compound [systematic name: 4-(5-methyl-3-phenyl-
isoxazol-4-yl)benzenesulfonamide], (I), is a non-steroidal anti-
in¯ammatory drug. A review on various aspects of valdecoxib
has recently been reported (Chavez & Dekorte, 2003). The
crystal structure of valdecoxib not containing any solvent, (II),
has already been reported (Malathy Sony et al., 2005).
A perspective view of (I) is shown in Fig. 1. Bond lengths
and angles can be regarded as normal (Cambridge Structural
Database, Version 1.6 plus three updates; MOGUL Version
1.0; Allen, 2002). The isoxazole heterocycle is planar (r.m.s.
deviation = 0.003 AÊ ). The dihedral angle between the
heterocycle and the phenyl ring is 34.56 (8) [22.2 (1) in (II)],
and 56.18 (8) [54.3 (1) in (II)] with the benzenesulfonamide
ring. The only remarkable difference between the molecular
conformations of (I) and (II) is the orientation of the
sulfonamide group. In (I), the amino group is on the same side
as the methyl group of the isoxazole ring. By contrast, in (II),
the amino group is on the same side as the phenyl ring
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attached to the isoxazole ring. The amino H atoms in (I) are
hydrogen bonded to sulfonyl O atoms of two different mol-
ecules. As a result, ribbons are formed along the b axis (Fig. 2).
In (II), only one H atom of the amino group forms a hydrogen
bond to a sulfonyl O atom. The other one forms an NÐH  
bond to the centre of the unsubstituted phenyl ring. These two
structures provide a good example of how the inclusion of
solvent molecules has an impact on either the molecular
conformation of a molecule or the formation of hydrogen
bonds.
Experimental
The title compound was obtained as a gift sample from Astral
Pharmaceuticals, Mumbai, India, and was used without further
puri®cation. Colourless plates were obtained from ethyl methyl
ketone by slow evaporation.
Crystal data
C16H14N2O3S0.5C4H8O
Mr = 350.40
Monoclinic, P21=c
a = 13.0201 (14) AÊ
b = 7.7930 (5) AÊ
c = 17.3305 (19) AÊ
 = 94.373 (9)
V = 1753.3 (3) AÊ 3
Z = 4
Dx = 1.327 Mg m
ÿ3
Mo K radiation
Cell parameters from 24 673
re¯ections
 = 3.5±25.7
 = 0.21 mmÿ1
T = 173 (2) K
Plate, colourless
0.40  0.37  0.14 mm
Data collection
Stoe IPDS-II two-circle
diffractometer
! scans
Absorption correction: multi-scan
(MULABS; Spek, 2003;
Blessing, 1995)
Tmin = 0.912, Tmax = 0.962
24 057 measured re¯ections
3345 independent re¯ections
2768 re¯ections with I > 2(I)
Rint = 0.057
max = 25.8

h = ÿ15! 15
k = ÿ9! 9
l = ÿ21! 21
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Figure 2
Packing diagram of the title compound, showing the hydrogen bonds as
dashed lines. The view is on to the ab plane. The solvent molecules have
been omitted for clarity.
Figure 1
Perspective view of the title compound, with the atom numbering.
Displacement ellipsoids are drawn at the 50% probability level. The ethyl
methyl ketone molecule is not shown.
Figure 3
A least-squares ®t (r.m.s. deviation = 0.238 AÊ for all atoms, except for the
S-bound O and N atoms) of the title compound (full bonds) with its
orthorhombic polymorph (open bonds).
Refinement
Re®nement on F 2
R[F 2 > 2(F 2)] = 0.044
wR(F 2) = 0.131
S = 1.06
3345 re¯ections
229 parameters
H atoms treated by a mixture of
independent and constrained
re®nement
w = 1/[2(Fo
2) + (0.0755P)2
+ 0.4033P]
where P = (Fo
2 + 2Fc
2)/3
(/)max = 0.001
max = 0.60 e AÊ
ÿ3
min = ÿ0.56 e AÊ ÿ3
Table 1
Selected bond lengths (AÊ ).
S1ÐO11 1.4280 (13)
S1ÐO12 1.4311 (13)
S1ÐN1 1.6036 (18)
S1ÐC14 1.7628 (18)
C1ÐC5 1.348 (3)
C1ÐC2 1.428 (3)
C2ÐN3 1.309 (3)
N3ÐO4 1.402 (2)
O4ÐC5 1.354 (2)
Table 2
Hydrogen-bonding geometry (AÊ , ).
DÐH  A DÐH H  A D  A DÐH  A
N1ÐH1A  O12i 0.85 (3) 2.05 (3) 2.881 (2) 165 (2)
N1ÐH1B  O11ii 0.81 (3) 2.09 (3) 2.863 (2) 160 (3)
Symmetry codes: (i) ÿx; yÿ 12; 12ÿ z; (ii) ÿx; 12 y; 12ÿ z.
The H atoms bonded to nitrogen were re®ned isotropically. Other
H atoms were re®ned with ®xed individual displacement parameters
[Uiso(H) = 1.2Ueq(C)] using a riding model, with CÐH = 0.98 and
0.95 AÊ for methyl and aromatic CH groups, respectively. In addition,
the methyl group was allowed to rotate but not to tip. There is half a
molecule of ethyl methyl ketone per asymmetric unit, which is
disordered about a centre of inversion.
Data collection: X-AREA (Stoe & Cie, 2001); cell re®nement:
X-AREA; data reduction: X-AREA; program(s) used to solve
structure: SHELXS97 (Sheldrick, 1990); program(s) used to re®ne
structure: SHELXL97 (Sheldrick, 1997); molecular graphics: XP in
SHELXTL-Plus (Sheldrick, 1991); software used to prepare material
for publication: SHELXL97 and PLATON (Spek, 2003).
One of the authors (HSY) thanks Astral Pharmaceuticals,
Mumbai, for a gift sample of valdecoxib.
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